首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   930852篇
  免费   67532篇
  国内免费   1341篇
耳鼻咽喉   12958篇
儿科学   24379篇
妇产科学   23232篇
基础医学   132928篇
口腔科学   28244篇
临床医学   80551篇
内科学   183308篇
皮肤病学   19229篇
神经病学   72176篇
特种医学   36807篇
外国民族医学   79篇
外科学   152092篇
综合类   18043篇
现状与发展   1篇
一般理论   234篇
预防医学   61738篇
眼科学   21348篇
药学   72545篇
  3篇
中国医学   2163篇
肿瘤学   57667篇
  2018年   8965篇
  2017年   7028篇
  2016年   7761篇
  2015年   8861篇
  2014年   11984篇
  2013年   17501篇
  2012年   24089篇
  2011年   25040篇
  2010年   14803篇
  2009年   14263篇
  2008年   24600篇
  2007年   25694篇
  2006年   26482篇
  2005年   25437篇
  2004年   24574篇
  2003年   23611篇
  2002年   23154篇
  2001年   54736篇
  2000年   56549篇
  1999年   46961篇
  1998年   10735篇
  1997年   9471篇
  1996年   9598篇
  1995年   8931篇
  1994年   8281篇
  1993年   7596篇
  1992年   35493篇
  1991年   33921篇
  1990年   32740篇
  1989年   31877篇
  1988年   29006篇
  1987年   28256篇
  1986年   26291篇
  1985年   25148篇
  1984年   17836篇
  1983年   15147篇
  1982年   7797篇
  1981年   6772篇
  1979年   15783篇
  1978年   10601篇
  1977年   9054篇
  1976年   7873篇
  1975年   8630篇
  1974年   10467篇
  1973年   9861篇
  1972年   9361篇
  1971年   8859篇
  1970年   8426篇
  1969年   7929篇
  1968年   7201篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
PURPOSE: The use of gefitinib, the first drug approved to inhibit the epidermal growth factor receptor tyrosine kinase, is indicated in patients with non-small-cell lung cancer with tumors progressive after chemotherapy. The unique mechanism of action of this agent leads to distinctive patterns of response and toxicity in persons with lung cancer. Many of the principles of management relevant to gefitinib are distinct from those with conventional cytotoxic drugs. To meet this need, we present practical guidelines on the use of gefitinib in patients with non-small-cell lung cancer. METHODS: This article reviews gefitinib's indications, dosing, response phenomena, and patterns of relapse in individuals with radiographic response. RESULTS: We present our recommendations for the management of rash and diarrhea caused by this agent. CONCLUSION: This information can guide practitioners and help them inform their patients about what to expect when they receive gefitinib.  相似文献   
993.
BACKGROUND: The impact of exercise programmes for heart failure on those close to the patient is largely unknown. We examined the effect of a hospital and home-based exercise intervention on burden, anxiety and depression of informal caregivers. DESIGN: The study was a randomized, controlled trial. Heart failure patients were randomized to a seated 12-week hospital-based exercise programme. Caregiver measures were gathered at baseline, 3 months later and 6 months following baseline. METHODS: Sixty caregivers (mean age 63.4 years, 65% female) of heart failure patients (n = 82, mean age 80.5 years, 44% female) participating in a trial of an exercise intervention were recruited. Caregiver burden, anxiety and depression were assessed. RESULTS: There were no differences in caregiver burden, depression or anxiety between the two groups of caregivers at baseline (caregiver burden, patient control 33.1 versus patient exercise 34.1; anxiety 4.1 versus 5.5; depression 2.8 versus 3.8). At 3 months there were no differences between caregivers in the two groups on outcomes. At 6-month follow-up caregivers of heart failure patients in the exercise group had burden scores that were significantly worse than the control group. There were no differences between the carers of exercise and control groups in anxiety and depression. Levels of anxiety and depression in the entire carer sample were marginally higher than reference values in a healthy non-clinical sample. CONCLUSION: The present exercise interventions for frail older patients did not benefit caregivers and was associated with an increase in caregiver burden. We suggest that future exercise interventions for heart failure patients should actively incorporate informal caregivers into research designs.  相似文献   
994.
995.
996.
997.
998.
999.
1000.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号